age
float64 18
102
| sex
stringclasses 2
values | hospdead
int64 0
1
| slos
int64 3
343
| dzgroup
stringclasses 8
values | dzclass
stringclasses 4
values | num.co
int64 0
9
| edu
float64 0
31
⌀ | income
stringclasses 4
values | scoma
float64 0
100
⌀ | charges
float64 1.17k
1.44M
⌀ | totcst
float64 0
633k
⌀ | totmcst
float64 -102.72
711k
⌀ | avtisst
float64 1
83
⌀ | race
stringclasses 5
values | sps
float64 0.2
99.2
⌀ | aps
float64 0
143
⌀ | surv2m
float64 0
0.97
⌀ | surv6m
float64 0
0.95
⌀ | hday
int64 1
148
| diabetes
int64 0
1
| dementia
int64 0
1
| ca
stringclasses 3
values | prg2m
float64 0
1
⌀ | prg6m
float64 0
1
⌀ | dnr
stringclasses 3
values | dnrday
float64 -88
285
⌀ | meanbp
float64 0
195
⌀ | wblc
float64 0
200
⌀ | hrt
float64 0
300
⌀ | resp
float64 0
90
⌀ | temp
float64 31.7
41.7
⌀ | pafi
float64 12
890
⌀ | alb
float64 0.4
29
⌀ | bili
float64 0.1
63
⌀ | crea
float64 0.1
21.5
⌀ | sod
float64 110
181
⌀ | ph
float64 6.83
7.77
⌀ | glucose
float64 0
1.09k
⌀ | bun
float64 1
300
⌀ | urine
float64 0
9k
⌀ | adlp
float64 0
7
⌀ | adls
float64 0
7
⌀ | sfdm2
stringclasses 5
values | adlsc
float64 0
7.07
| event_times
int64 3
2.03k
| event_indicators
int64 0
1
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
71.66095
|
male
| 0
| 11
|
Colon Cancer
|
Cancer
| 2
| 18
|
under $11k
| 0
| 20,083
| 11,667.2031
| 10,053
| 7.5
|
hispanic
| 17.597656
| 13
| 0.795898
| 0.56897
| 1
| 0
| 0
|
metastatic
| null | null |
no dnr
| 11
| 103
| 12
| 84
| 16
| 36.59375
| null | 3.899902
| 0.599976
| 0.899902
| 139
| null | 140
| 8
| 4,150
| null | 1
|
no(M2 and SIP pres)
| 1
| 313
| 1
|
70.59497
|
male
| 0
| 17
|
MOSF w/Malig
|
ARF/MOSF
| 1
| 17
| null | 0
| 44,516
| null | null | 21.666656
|
white
| 30.097656
| 42
| 0.5
| 0.382996
| 3
| 0
| 0
|
yes
| 0.8
| 0.7
|
no dnr
| 17
| 57
| 0.099991
| 146
| 27
| 35.89844
| 177.5
| 2.199707
| 0.799927
| 4.5
| 142
| 7.349609
| 209
| 97
| 185
| null | 1
|
<2 mo. follow-up
| 1
| 26
| 1
|
47.75598
|
male
| 1
| 7
|
Coma
|
Coma
| 1
| null | null | 44
| 20,038
| null | null | 24
|
black
| 20.796875
| 35
| 0.716919
| 0.664917
| 1
| 0
| 0
|
no
| null | null |
dnr after sadm
| 4
| 117
| 11.599609
| 134
| 21
| 37.09375
| 274.25
| null | 0.5
| 2.099609
| 135
| 7.369141
| 97
| 67
| 2,030
| null | null |
<2 mo. follow-up
| 1.883301
| 7
| 1
|
49.52197
|
female
| 0
| 9
|
MOSF w/Malig
|
ARF/MOSF
| 1
| 14
|
$25-$50k
| 0
| 53,838
| null | null | 16.5
|
white
| 25.296875
| 43
| 0.540894
| 0.426941
| 9
| 0
| 0
|
metastatic
| null | null |
no dnr
| 9
| 117
| 10.5
| 64
| 10
| 38.39844
| 312
| null | null | 0.599976
| 141
| 7.399414
| 111
| 7
| 4,050
| 0
| 1
|
no(M2 and SIP pres)
| 1
| 1,026
| 0
|
67.50397
|
female
| 0
| 8
|
Lung Cancer
|
Cancer
| 1
| 14
|
>$50k
| 0
| 12,570
| null | null | 18
|
white
| 28.5
| 13
| 0.406982
| 0.107986
| 1
| 0
| 0
|
metastatic
| null | null |
no dnr
| 8
| 130
| 7.5
| 116
| 26
| 36
| 323.3125
| null | 0.599976
| 1.5
| 138
| 7.399414
| 253
| 44
| 2,350
| 6
| 7
| null | 7
| 64
| 1
|
45.89999
|
male
| 0
| 12
|
Lung Cancer
|
Cancer
| 0
| 10
|
$11-$25k
| 0
| 10,337
| null | null | 7
|
hispanic
| 28.796875
| 12
| 0.472961
| 0.156982
| 1
| 0
| 0
|
metastatic
| 0.8
| 0.6
|
no dnr
| 12
| 71
| 6.699219
| 54
| 20
| 36.5
| null | null | null | 1.199951
| 138
| null | 72
| 12
| 2,160
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 212
| 1
|
35.099
|
male
| 0
| 15
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 12
| null | 61
| 50,602
| null | null | 18
|
white
| 30.597656
| 52
| 0.611938
| 0.505981
| 1
| 0
| 0
|
no
| 0.6
| 0.5
|
no dnr
| 15
| 69
| 10.599609
| 70
| 12
| 36.5
| 253.3125
| null | null | 0.899902
| 134
| 7.469727
| 130
| 23
| 1,170
| null | 5
|
SIP>=30
| 5
| 1,025
| 0
|
50.43399
|
female
| 0
| 25
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 9
| null | 0
| 155,353
| null | null | 33.25
|
black
| 29.5
| 54
| 0.700928
| 0.610962
| 20
| 0
| 0
|
no
| 0.6
| 0.5
|
no dnr
| 25
| 76
| 16.898438
| 126
| 32
| 37.69531
| 105
| null | null | 1
| 137
| 7.479492
| 134
| 22
| 3,320
| null | 0
| null | 0
| 61
| 1
|
65.23999
|
male
| 1
| 58
|
MOSF w/Malig
|
ARF/MOSF
| 1
| 16
|
$25-$50k
| 44
| 205,279
| null | null | 33.5
|
white
| 32.296875
| 57
| 0.161987
| 0.079987
| 14
| 0
| 0
|
yes
| null | null |
dnr after sadm
| 49
| 58
| 11
| 96
| 36
| 36.59375
| 304
| null | null | 2.099609
| 133
| 7.509766
| 165
| 60
| 4,485
| null | 0
|
<2 mo. follow-up
| 0
| 58
| 1
|
74.57397
|
female
| 1
| 5
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 12
|
under $11k
| 0
| 93,795
| null | null | 41
|
white
| 45
| 76
| 0.078995
| 0.029999
| 20
| 0
| 0
|
yes
| 0.2
| 0.05
|
no dnr
| 5
| 73
| 5.799805
| 70
| 16
| 36.5
| null | 3.899902
| 1.899902
| 1.299805
| 136
| null | 155
| 25
| 1,400
| null | 1
|
<2 mo. follow-up
| 1
| 5
| 1
|
67.81696
|
male
| 1
| 8
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 11
|
>$50k
| 0
| 53,038
| null | null | 47
|
white
| 49
| 82
| 0.155975
| 0.075989
| 2
| 0
| 0
|
no
| 0.6
| 0.4
|
dnr after sadm
| 6
| 79
| 10
| 70
| 20
| 36.79688
| null | null | 0.899902
| 1.5
| 142
| null | 153
| 22
| null | null | 0
|
<2 mo. follow-up
| 0
| 8
| 1
|
79.21698
|
female
| 0
| 71
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 8
|
$11-$25k
| 0
| 175,574
| 120,693.125
| 87,405
| 40.25
|
white
| 27.398438
| 37
| 0.688965
| 0.596924
| 1
| 0
| 0
|
no
| 0.5
| 0.45
|
no dnr
| 71
| 103
| 9.398438
| 114
| 35
| 36.39844
| 433.3125
| null | null | 0.899902
| 131
| 7.429688
| 343
| 13
| 1,555
| null | 0
|
SIP>=30
| 0
| 1,023
| 0
|
70.75696
|
male
| 1
| 8
|
COPD
|
COPD/CHF/Cirrhosis
| 0
| 3
|
$11-$25k
| 41
| 39,964
| null | null | 35.5
|
white
| 27.097656
| 43
| 0.490967
| 0.28894
| 6
| 0
| 0
|
no
| 0.25
| 0.05
|
dnr after sadm
| 4
| 63
| 6.299805
| 116
| 20
| 38.19531
| null | null | 0.599976
| 0.599976
| 139
| null | 96
| 8
| null | null | 0
|
<2 mo. follow-up
| 0
| 8
| 1
|
65.74097
|
male
| 0
| 40
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 12
| null | 0
| 144,457
| 96,665.3125
| 75,360
| 24.5
|
white
| 22.5
| 27
| 0.778931
| 0.706909
| 8
| 0
| 0
|
no
| 0.5
| 0.45
|
no dnr
| 40
| 73
| 8.398438
| 66
| 28
| 36
| null | null | 0.799927
| 3.599609
| 136
| null | 196
| 92
| 1,030
| null | 0
|
no(M2 and SIP pres)
| 0
| 1,021
| 0
|
63.33197
|
male
| 0
| 8
|
Colon Cancer
|
Cancer
| 1
| 9
|
$25-$50k
| 0
| 10,891
| null | null | 10
|
white
| 14.5
| 5
| 0.850952
| 0.669922
| 1
| 0
| 0
|
metastatic
| null | null |
no dnr
| 8
| 145
| 7
| 146
| 24
| 38.09375
| 596
| 3
| 0.5
| 0.899902
| 137
| 7.449219
| 98
| 4
| 3,300
| 1
| 0
|
no(M2 and SIP pres)
| 0
| 143
| 1
|
64.63196
|
female
| 0
| 14
|
MOSF w/Malig
|
ARF/MOSF
| 1
| 11
| null | 0
| 50,961
| null | null | 20.666656
|
white
| 20.097656
| 35
| 0.642944
| 0.541992
| 10
| 0
| 0
|
metastatic
| 0.1
| 0
|
dnr after sadm
| 3
| 41
| 2.399902
| 126
| 18
| 35.79688
| 115
| 2
| 6.599609
| 2
| 133
| 7.329102
| 42
| 31
| 360
| null | 0
|
<2 mo. follow-up
| 0
| 29
| 1
|
58.59799
|
female
| 1
| 6
|
MOSF w/Malig
|
ARF/MOSF
| 2
| 0
|
under $11k
| 0
| 47,649
| null | null | 48
|
white
| 36.5
| 44
| 0.201996
| 0.108994
| 9
| 1
| 0
|
metastatic
| 0.4
| 0.1
|
dnr after sadm
| 3
| 134
| 14.5
| 120
| 34
| 36.39844
| 226.65625
| null | 0.399963
| 2.899902
| 138
| 7.239258
| 155
| 61
| 2,070
| null | 7
|
<2 mo. follow-up
| 7
| 6
| 1
|
56.63199
|
male
| 1
| 7
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 12
|
under $11k
| 9
| 77,474
| null | null | 41.5
|
white
| 23
| 29
| 0.782959
| 0.712891
| 7
| 0
| 0
|
no
| null | null |
dnr after sadm
| 6
| 112
| 22.597656
| 67
| 20
| 36.79688
| null | 3.299805
| 1
| 1.299805
| 136
| null | 93
| 16
| 700
| null | 0
|
<2 mo. follow-up
| 0
| 7
| 1
|
84.50696
|
male
| 1
| 10
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 8
| null | 0
| 57,715
| null | null | 34.5
|
white
| 25.597656
| 45
| 0.629883
| 0.527954
| 8
| 0
| 0
|
no
| null | null |
dnr after sadm
| 2
| 78
| 7.199219
| 75
| 22
| 34.69531
| 450
| null | null | 1.399902
| 138
| 7.459961
| 101
| 23
| 1,450
| null | null |
<2 mo. follow-up
| 3.116211
| 10
| 1
|
71.02496
|
female
| 1
| 7
|
Coma
|
Coma
| 0
| 13
| null | 100
| 21,937
| null | null | 26.5
|
black
| 20.597656
| 38
| 0.242981
| 0.176971
| 1
| 0
| 0
|
no
| 0.05
| 0.05
|
dnr after sadm
| 4
| 116
| 11
| 160
| 10
| 38.19531
| 266.625
| null | null | 0.899902
| 128
| 7.489258
| 144
| 16
| 2,700
| null | 0
|
<2 mo. follow-up
| 0
| 7
| 1
|
55.22498
|
male
| 0
| 7
|
COPD
|
COPD/CHF/Cirrhosis
| 1
| null | null | 0
| 7,268
| null | null | 7
|
black
| 13.798828
| 27
| 0.938965
| 0.895996
| 1
| 0
| 0
|
no
| 0.8
| 0.6
|
no dnr
| 7
| 73
| 8.099609
| 130
| 22
| 37.69531
| 212.5
| 2.599609
| 1.599854
| 0.899902
| 137
| 7.389648
| 107
| 18
| 1,000
| 0
| 1
|
no(M2 and SIP pres)
| 1
| 1,017
| 0
|
76.81897
|
male
| 1
| 8
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 8
|
$11-$25k
| 26
| 53,023
| null | null | 39.5
|
white
| 38
| 56
| 0.15097
| 0.072998
| 5
| 0
| 0
|
yes
| 0.5
| 0.4
|
dnr after sadm
| 6
| 136
| 14.199219
| 126
| 30
| 37.89844
| 127.5
| 2.399902
| 0.399963
| 1.199951
| 143
| 7.399414
| 181
| 56
| 2,390
| null | 1
|
<2 mo. follow-up
| 1
| 8
| 1
|
69.17499
|
male
| 0
| 69
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 8
| null | 0
| 176,045
| 118,669.938
| 107,170
| 25
|
white
| 34.296875
| 41
| 0.528931
| 0.41394
| 4
| 0
| 0
|
no
| 0.9
| 0.8
|
no dnr
| 69
| 49
| 10.5
| 134
| 35
| 36.09375
| 39
| null | 0.399963
| 0.399963
| 128
| 7.419922
| 169
| 12
| 1,835
| null | 6
|
adl>=4 (>=5 if sur)
| 6
| 1,016
| 0
|
29.59299
|
female
| 0
| 20
|
MOSF w/Malig
|
ARF/MOSF
| 3
| 12
|
$11-$25k
| 0
| 62,432
| null | null | 20
|
white
| 24.5
| 51
| 0.662964
| 0.564941
| 10
| 0
| 0
|
yes
| 0.8
| 0.75
|
no dnr
| 20
| 109
| 21.5
| 60
| 8
| 38.19531
| 214.28125
| 2.799805
| null | 0.599976
| 134
| 7.439453
| 94
| 16
| 1,390
| 1
| 0
|
no(M2 and SIP pres)
| 0
| 507
| 1
|
66.18195
|
female
| 0
| 12
|
Colon Cancer
|
Cancer
| 1
| 12
|
$11-$25k
| 0
| 15,025
| null | null | 16
|
white
| 25
| 19
| 0.674927
| 0.377991
| 1
| 0
| 0
|
metastatic
| 0.75
| 0.5
|
no dnr
| 12
| 79
| 14.199219
| 66
| 22
| 36.69531
| 245.6875
| null | null | 5.599609
| 141
| 7.429688
| 207
| 50
| 483
| 0
| 0
|
<2 mo. follow-up
| 0
| 58
| 1
|
67.93994
|
male
| 0
| 9
|
Lung Cancer
|
Cancer
| 2
| 10
|
under $11k
| 0
| 11,082
| null | null | 9.5
|
black
| 21.5
| 39
| 0.599976
| 0.281982
| 1
| 0
| 0
|
metastatic
| 0.7
| 0.4
|
no dnr
| 9
| 131
| 16.5
| 154
| 25
| 34.5
| 90
| 1.5
| 0.299988
| 3.199707
| 135
| 7.439453
| 271
| 41
| 165
| 1
| 4
|
no(M2 and SIP pres)
| 4
| 227
| 1
|
29.09499
|
male
| 0
| 6
|
CHF
|
COPD/CHF/Cirrhosis
| 3
| 10
| null | 0
| 2,940
| null | null | 7
|
black
| 19
| 23
| 0.939941
| 0.897949
| 1
| 0
| 0
|
no
| null | null |
no dnr
| 6
| 111
| 18.398438
| 134
| 36
| 36.5
| 115
| null | 1.899902
| 1
| 142
| 7.40918
| 288
| 21
| 1,270
| 0
| 0
|
SIP>=30
| 0
| 1,014
| 0
|
63.573
|
male
| 0
| 12
|
Colon Cancer
|
Cancer
| 1
| 3
|
under $11k
| 0
| 32,942
| 18,734.1562
| 17,499
| 22.5
|
other
| 38.59375
| 21
| 0.317993
| 0.057999
| 1
| 0
| 0
|
metastatic
| null | null |
no dnr
| 12
| 74
| 11
| 80
| 30
| 36.89844
| 246
| 2.699707
| null | 0.5
| 117
| 7.5
| 106
| 9
| 2,840
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 1,013
| 0
|
72.71497
|
female
| 1
| 22
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| null | null | 0
| 67,741
| null | null | 23
|
white
| 27.597656
| 56
| 0.625977
| 0.521973
| 21
| 0
| 0
|
no
| 0.3
| 0.15
|
dnr after sadm
| 5
| 103
| 4.099609
| 110
| 9
| 37.89844
| 225.6875
| null | 0.699951
| 3.599609
| 143
| 7.329102
| 91
| 81
| 2,357
| null | 5
|
<2 mo. follow-up
| 5
| 22
| 1
|
60.01398
|
male
| 0
| 20
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 12
|
under $11k
| 0
| 94,502
| 63,838.9688
| 52,158
| 24
|
white
| 30.5
| 44
| 0.667969
| 0.571899
| 5
| 0
| 0
|
no
| 0.6
| 0.6
|
no dnr
| 20
| 69
| 19.699219
| 76
| 31
| 36.59375
| 433.3125
| null | 0.899902
| 3.299805
| 138
| 7.449219
| 103
| 98
| 1,835
| null | null |
no(M2 and SIP pres)
| 2.320313
| 1,012
| 0
|
71.66895
|
male
| 0
| 9
|
CHF
|
COPD/CHF/Cirrhosis
| 2
| null | null | 0
| 10,752
| null | null | 9
|
white
| 21.296875
| 23
| 0.824951
| 0.714966
| 1
| 0
| 0
|
no
| 0.8
| 0.8
|
no dnr
| 9
| 73
| 1.799805
| 116
| 32
| 35.39844
| 92.29688
| null | 19.597656
| 3.799805
| 128
| 7.449219
| 177
| 106
| 4,090
| null | null | null | 2.635742
| 1,012
| 0
|
30.853
|
male
| 0
| 9
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 1
|
$25-$50k
| 0
| 14,503
| null | null | 15.5
|
white
| 20.296875
| 16
| 0.920898
| 0.891968
| 1
| 0
| 0
|
no
| 1
| 1
|
no dnr
| 9
| 87
| 27.398438
| 206
| 34
| 38.5
| 130
| 3.299805
| 6.899414
| 4
| 126
| 7.329102
| 668
| 86
| 107
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 1,012
| 0
|
47.09399
|
female
| 0
| 29
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 17
| null | 9
| 48,037
| null | null | 21.5
|
white
| 22.398438
| 42
| 0.859985
| 0.810913
| 1
| 0
| 0
|
no
| 0.8
| 0.8
|
no dnr
| 29
| 53
| 16.097656
| 76
| 29
| 38
| 146.9375
| 1.799805
| 4.599609
| 1.199951
| 148
| 7.449219
| 81
| 19
| 3,770
| null | 0
|
SIP>=30
| 0
| 1,012
| 0
|
49.35199
|
male
| 0
| 4
|
CHF
|
COPD/CHF/Cirrhosis
| 3
| 14
|
>$50k
| 0
| 5,036
| null | null | 6
|
hispanic
| 20
| 15
| 0.899902
| 0.831909
| 1
| 0
| 0
|
no
| null | null |
no dnr
| 4
| 108
| 6.899414
| 96
| 22
| 38.69531
| null | 3.599609
| 0.599976
| 0.899902
| 136
| null | 69
| 14
| 3,700
| 0
| null |
no(M2 and SIP pres)
| 0.494751
| 1,012
| 0
|
59.35397
|
male
| 0
| 29
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 14
| null | 0
| 96,798
| 58,078.9375
| 53,137
| 27.5
|
white
| 22
| 32
| 0.837891
| 0.782959
| 2
| 1
| 0
|
no
| 0.3
| 0.2
|
no dnr
| 29
| 77
| 7.399414
| 54
| 22
| 36.19531
| 270
| 2.729981
| null | 4.199219
| 131
| 7.529297
| 82
| 64
| 2,190
| null | 0
|
no(M2 and SIP pres)
| 0
| 1,009
| 0
|
81.78796
|
female
| 0
| 8
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 6
| null | 9
| 30,732
| null | null | 10.5
|
white
| 21.398438
| 36
| 0.731934
| 0.648926
| 3
| 0
| 0
|
no
| 0.95
| 0.9
|
no dnr
| 8
| 56
| 15.5
| 106
| 10
| 36.59375
| 324
| 2.5
| 4.599609
| 3.799805
| 145
| 7.30957
| 95
| 62
| 2,367
| null | 1
|
no(M2 and SIP pres)
| 1
| 1,009
| 0
|
74.56494
|
male
| 0
| 18
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 3
|
$11-$25k
| 0
| 65,352
| null | null | 30.666656
|
black
| 29.597656
| 33
| 0.666992
| 0.569946
| 1
| 0
| 0
|
no
| 0.5
| 0.4
|
no dnr
| 18
| 103
| 8.199219
| 116
| 26
| 36.79688
| 211.40625
| 3.299805
| null | 8.199219
| 133
| 7.329102
| 184
| 103
| 1,260
| null | 0
|
no(M2 and SIP pres)
| 0
| 1,009
| 0
|
19.866
|
female
| 0
| 26
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 12
|
$25-$50k
| 0
| 44,245
| 27,406.2344
| 26,054
| 15.5
|
white
| 24.296875
| 30
| 0.912964
| 0.880981
| 1
| 0
| 0
|
no
| 0.9
| 0.9
|
no dnr
| 26
| 73
| 3
| 114
| 24
| 36.79688
| null | 2
| 13.798828
| 0.699951
| 129
| null | 160
| 9
| 3,050
| 3
| 4
|
no(M2 and SIP pres)
| 4
| 1,009
| 0
|
54.17398
|
male
| 0
| 6
|
Colon Cancer
|
Cancer
| 1
| 12
|
>$50k
| 0
| 9,281
| null | null | 10
|
white
| 17.5
| 12
| 0.829956
| 0.630981
| 1
| 0
| 0
|
metastatic
| null | null |
no dnr
| 6
| 129
| 13.199219
| 96
| 55
| 36.09375
| 292
| null | null | 0.699951
| 135
| 7.389648
| 184
| 21
| 1,480
| 0
| 1
|
no(M2 and SIP pres)
| 1
| 459
| 1
|
72.38098
|
male
| 1
| 63
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 3
| 16
| null | 0
| 215,817
| 140,466
| 116,142
| 30
|
white
| 23.199219
| 24
| 0.758911
| 0.682983
| 4
| 1
| 0
|
no
| 0.6
| 0.55
|
dnr after sadm
| 61
| 117
| 25.699219
| 106
| 30
| 35.69531
| 172.5
| null | null | 1.199951
| 143
| 7.479492
| 124
| 31
| 2,830
| 0
| 0
| null | 0
| 63
| 1
|
39.11298
|
female
| 1
| 65
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 12
| null | 0
| 211,744
| 147,594.125
| 121,504
| 33.5
|
black
| 37.398438
| 76
| 0.622925
| 0.518921
| 5
| 0
| 0
|
no
| 0.4
| 0.4
|
dnr after sadm
| 54
| 89
| 8.599609
| 94
| 24
| 36.89844
| 309.5
| 2.799805
| 0.599976
| 0.599976
| 140
| 7.40918
| 158
| 8
| 2,025
| null | 6
| null | 6
| 65
| 1
|
45.50598
|
male
| 1
| 13
|
Cirrhosis
|
COPD/CHF/Cirrhosis
| 3
| 15
|
$25-$50k
| 44
| 136,951
| null | null | 51.5
|
white
| 28.296875
| 46
| 0.514893
| 0.313965
| 4
| 0
| 0
|
no
| 0.2
| 0.2
|
no dnr
| 13
| 114
| 9.298828
| 70
| 24
| 36.69531
| null | null | null | 1.299805
| 141
| null | 97
| 24
| null | null | 0
|
<2 mo. follow-up
| 0
| 13
| 1
|
38.00098
|
male
| 0
| 10
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 12
|
>$50k
| 0
| 20,619
| null | null | 15
|
white
| 19.296875
| 29
| 0.916992
| 0.886963
| 1
| 0
| 0
|
no
| 0.9
| 0.9
|
no dnr
| 10
| 97
| 18.5
| 170
| 60
| 36.19531
| 216.65625
| null | 0.5
| 0.799927
| 132
| 7.469727
| 144
| 12
| 3,716
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 1,007
| 0
|
82.57098
|
female
| 1
| 8
|
COPD
|
COPD/CHF/Cirrhosis
| 2
| 12
|
under $11k
| 0
| 18,749
| null | null | 24.5
|
white
| 23.5
| 40
| 0.700928
| 0.537964
| 1
| 0
| 0
|
no
| 0.5
| 0.5
|
dnr after sadm
| 4
| 48
| 0.099991
| 124
| 11
| 35.29688
| 444
| 1.199951
| 0.599976
| 1.599854
| 133
| 7.369141
| 76
| 23
| 1,430
| null | 1
|
<2 mo. follow-up
| 1
| 8
| 1
|
60.84299
|
female
| 0
| 11
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 12
| null | 0
| 54,325
| null | null | 35.5
|
white
| 18.097656
| 10
| 0.875977
| 0.831909
| 2
| 0
| 0
|
no
| 0.9
| 0.8
|
no dnr
| 11
| 106
| 60
| 74
| 22
| 36.39844
| 417.375
| null | null | 6.399414
| 142
| 7.319336
| 70
| 59
| null | null | 0
|
no(M2 and SIP pres)
| 0
| 1,006
| 0
|
47.39499
|
male
| 1
| 8
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 4
| null | null | 44
| 27,011
| 18,225.9375
| 15,042
| 31
|
black
| 41
| 84
| 0.320984
| 0.20697
| 1
| 0
| 0
|
no
| 0.2
| 0.1
|
dnr after sadm
| 4
| 112
| 18
| 60
| 40
| 38.09375
| null | null | null | 0.799927
| 139
| null | 179
| 11
| 575
| null | null |
<2 mo. follow-up
| 3.375
| 8
| 1
|
57.728
|
male
| 0
| 6
|
Lung Cancer
|
Cancer
| 2
| 18
|
>$50k
| 0
| 13,046
| null | null | 17
|
white
| 13.798828
| 18
| 0.779907
| 0.539917
| 1
| 1
| 0
|
metastatic
| 0.8
| 0.6
|
no dnr
| 6
| 105
| 5.899414
| 86
| 24
| 37.69531
| null | null | 0.399963
| 0.599976
| 131
| null | 151
| 6
| null | 0
| 0
| null | 0
| 86
| 1
|
62.49698
|
female
| 1
| 3
|
MOSF w/Malig
|
ARF/MOSF
| 2
| 9
| null | 0
| 73,631
| null | null | 45
|
other
| 79.59375
| 104
| 0
| 0
| 1
| 1
| 0
|
metastatic
| 0
| 0
|
dnr after sadm
| 3
| 110
| 6.599609
| 96
| 16
| 35.69531
| null | null | 0.299988
| 0.799927
| 138
| null | 185
| 17
| 2,225
| null | null |
<2 mo. follow-up
| 1.454102
| 3
| 1
|
61.09
|
female
| 1
| 5
|
Coma
|
Coma
| 1
| 10
| null | 61
| 16,863
| null | null | 20
|
black
| 16.097656
| 25
| 0.652954
| 0.593994
| 1
| 0
| 0
|
no
| 0.1
| 0.1
|
dnr after sadm
| 5
| 73
| 51.398438
| 106
| 36
| 36.5
| 126.51562
| 2.5
| 1.599854
| 1.199951
| 150
| 7.479492
| 100
| 34
| 1,810
| null | 0
|
<2 mo. follow-up
| 0
| 5
| 1
|
55.017
|
female
| 1
| 4
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 3
| 3
|
under $11k
| 9
| 27,510
| null | null | 47
|
white
| 55.09375
| 93
| 0.017998
| 0.004
| 6
| 0
| 0
|
yes
| 0
| 0
|
dnr after sadm
| 1
| 111
| 16.097656
| 126
| 18
| 37.79688
| 340
| 2.199707
| 1.199951
| 0.699951
| 141
| 7.529297
| 156
| 24
| 975
| null | 1
|
<2 mo. follow-up
| 1
| 4
| 1
|
73.86694
|
male
| 0
| 13
|
CHF
|
COPD/CHF/Cirrhosis
| 2
| 19
|
>$50k
| 0
| 60,145
| 34,741.5312
| 34,546
| 34
|
white
| 22.699219
| 27
| 0.772949
| 0.638916
| 3
| 0
| 0
|
no
| 0.8
| 0.7
|
no dnr
| 13
| 57
| 12.798828
| 116
| 28
| 38
| 276
| null | null | 1.099854
| 130
| 7.389648
| 176
| 20
| 2,065
| null | 0
|
no(M2 and SIP pres)
| 0
| 174
| 1
|
46.349
|
female
| 0
| 41
|
COPD
|
COPD/CHF/Cirrhosis
| 1
| 14
|
$11-$25k
| 0
| 104,262
| 69,474.75
| 61,195
| 26.25
|
white
| 19.5
| 35
| 0.929932
| 0.879883
| 1
| 0
| 0
|
no
| 0.5
| 0.5
|
no dnr
| 41
| 73
| 10.099609
| 60
| 16
| 35.69531
| null | 2.699707
| 0.5
| 0.599976
| 139
| null | 133
| 10
| 3,350
| null | 0
|
no(M2 and SIP pres)
| 0
| 1,004
| 0
|
33.56598
|
female
| 0
| 18
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 13
|
$25-$50k
| 0
| 67,523
| null | null | 23.333328
|
white
| 23.296875
| 44
| 0.876953
| 0.833984
| 4
| 0
| 0
|
no
| 0.8
| 0.8
|
no dnr
| 18
| 82
| 19.796875
| 120
| 24
| 36
| null | 3
| 0.5
| 0.699951
| 137
| null | 145
| 12
| null | null | 0
|
no(M2 and SIP pres)
| 0
| 1,002
| 0
|
52.44897
|
male
| 0
| 5
|
Lung Cancer
|
Cancer
| 1
| 11
|
under $11k
| 0
| 6,349
| null | null | 23
|
white
| 17.097656
| 13
| 0.733887
| 0.464966
| 1
| 0
| 0
|
metastatic
| 1
| 0.8
|
no dnr
| 5
| 133
| 2.199707
| 136
| 26
| 36.29688
| 308
| 2.299805
| 1
| 1.199951
| 155
| 7.509766
| 95
| 35
| 3,765
| 0
| null |
no(M2 and SIP pres)
| 0.494751
| 328
| 1
|
45.25098
|
male
| 0
| 32
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 16
| null | 0
| 144,548
| null | null | 36.25
|
black
| 33.695313
| 49
| 0.69397
| 0.602905
| 3
| 0
| 0
|
no
| 0.5
| 0.5
|
no dnr
| 32
| 162
| 5.799805
| 126
| 8
| 38.69531
| 303.3125
| 2.599609
| 4.5
| 3
| 136
| 7.429688
| 59
| 121
| 2,195
| null | null |
no(M2 and SIP pres)
| 1.995117
| 1,001
| 0
|
51.58698
|
female
| 0
| 12
|
MOSF w/Malig
|
ARF/MOSF
| 1
| 11
|
under $11k
| 0
| 23,850
| 15,265.5391
| 15,398
| 23
|
other
| 33.5
| 35
| 0.369995
| 0.251953
| 2
| 0
| 0
|
metastatic
| 0.6
| 0.3
|
no dnr
| 12
| 59
| 2.299805
| 124
| 40
| 38.19531
| 172.5
| null | 1
| 0.899902
| 151
| 7.479492
| 171
| 31
| 1,790
| null | 0
| null | 0
| 199
| 1
|
27.644
|
male
| 1
| 5
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 11
|
$11-$25k
| 9
| 55,573
| null | null | 37
|
black
| 33.898438
| 64
| 0.724976
| 0.639893
| 5
| 0
| 0
|
no
| 0.9
| 0.9
|
no dnr
| 5
| 51
| 0.299988
| 124
| 30
| 35.19531
| 168.5625
| null | null | 1.399902
| 132
| 7.349609
| 164
| 50
| 1,091
| null | null |
<2 mo. follow-up
| 1.954834
| 5
| 1
|
44.08197
|
male
| 0
| 24
|
Cirrhosis
|
COPD/CHF/Cirrhosis
| 3
| 12
|
under $11k
| 9
| 45,380
| 28,963.5625
| 31,141
| 20
|
white
| 32.59375
| 56
| 0.631958
| 0.448975
| 1
| 0
| 0
|
no
| 0.6
| 0.4
|
no dnr
| 24
| 39
| 16.296875
| 124
| 32
| 38.29688
| 113.75
| null | 0.799927
| 2.099609
| 128
| 7.339844
| 215
| 47
| 2,920
| null | 0
|
no(M2 and SIP pres)
| 0
| 998
| 0
|
79.67096
|
male
| 0
| 28
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| null |
under $11k
| 0
| 57,108
| 34,602.7188
| 33,933
| 25.25
|
white
| 21.199219
| 24
| 0.796997
| 0.72998
| 1
| 0
| 0
|
no
| 0.3
| 0.15
|
dnr after sadm
| 2
| 46
| 4.399414
| 74
| 10
| 38.89844
| 197.5
| 1.699951
| null | 0.899902
| 135
| 7.419922
| 115
| 17
| 1,830
| null | 6
|
adl>=4 (>=5 if sur)
| 6
| 515
| 1
|
67.09094
|
male
| 0
| 10
|
CHF
|
COPD/CHF/Cirrhosis
| 3
| 12
|
$25-$50k
| 0
| null | null | null | 26.5
|
white
| 16.398438
| 33
| 0.889893
| 0.816895
| 1
| 1
| 0
|
no
| 0.85
| 0.75
| null | null | 52
| 11.099609
| 110
| 42
| 38.69531
| 253.3125
| null | null | 1.299805
| 148
| 7.429688
| 135
| 31
| 3,065
| 0
| 4
|
no(M2 and SIP pres)
| 4
| 568
| 1
|
100.67896
|
male
| 1
| 4
|
COPD
|
COPD/CHF/Cirrhosis
| 2
| 8
|
under $11k
| 0
| 3,920
| null | null | 8
|
black
| 33.398438
| 41
| 0.22699
| 0.075989
| 1
| 1
| 0
|
no
| 0.5
| 0.5
|
dnr after sadm
| 1
| 70
| 5.399414
| 64
| 8
| 35.79688
| 177.5
| null | null | 1.299805
| 138
| 7.5
| 128
| 38
| 1,545
| null | 7
|
<2 mo. follow-up
| 7
| 4
| 1
|
84.13995
|
female
| 1
| 21
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| null | null | 0
| 105,122
| 61,753.4375
| 64,790
| 35
|
white
| 29.597656
| 77
| 0.526978
| 0.41095
| 9
| 0
| 0
|
no
| 0.4
| 0.3
|
dnr after sadm
| 3
| 83
| 7.099609
| 73
| 20
| 37.59375
| null | 3.299805
| 0.299988
| 1
| 143
| null | 100
| 10
| null | null | 1
|
<2 mo. follow-up
| 1
| 21
| 1
|
56.71198
|
female
| 1
| 14
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 10
|
$25-$50k
| 0
| 88,913
| 55,612.4375
| 46,654
| 44.666657
|
white
| 32.59375
| 56
| 0.612915
| 0.506958
| 11
| 1
| 0
|
no
| 0.5
| 0.4
|
dnr after sadm
| 12
| 134
| 17.699219
| 224
| 8
| 37.89844
| 330
| 2.199707
| 0.5
| 0.899902
| 135
| 7.489258
| 85
| 16
| 2,750
| null | 1
|
<2 mo. follow-up
| 1
| 14
| 1
|
53.00497
|
male
| 0
| 4
|
Lung Cancer
|
Cancer
| 1
| 12
|
>$50k
| 0
| 3,597
| 2,311.5449
| 1,932
| 10
|
white
| 16.898438
| 19
| 0.737915
| 0.470947
| 1
| 0
| 0
|
metastatic
| 0.8
| 0.5
|
no dnr
| 4
| 49
| 17
| 134
| 12
| 38.59375
| 140
| null | null | 0.5
| 133
| 7.359375
| 150
| 16
| 665
| null | 0
| null | 0
| 107
| 1
|
72.31494
|
female
| 1
| 13
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 3
|
under $11k
| 37
| 75,777
| 48,117.125
| 38,192
| 47
|
black
| 27.699219
| 45
| 0.511963
| 0.394958
| 4
| 1
| 0
|
no
| 0.3
| 0.2
|
dnr after sadm
| 12
| 139
| 16
| 114
| 32
| 38.59375
| 324
| null | 0.599976
| 0.5
| 136
| 7.449219
| 278
| 19
| 5,190
| null | 6
|
<2 mo. follow-up
| 6
| 13
| 1
|
70.31097
|
male
| 0
| 30
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 16
|
$25-$50k
| 0
| 70,800
| 52,140.75
| 42,268
| 21.75
|
white
| 23.597656
| 32
| 0.794922
| 0.726929
| 1
| 0
| 0
|
no
| 0.6
| 0.5
|
no dnr
| 30
| 61
| 11.099609
| 76
| 31
| 38.19531
| 191.40625
| 2.899902
| 2.599609
| 4.699219
| 142
| 7.379883
| 80
| 90
| 2,215
| null | null |
no(M2 and SIP pres)
| 2.033691
| 992
| 0
|
61.72498
|
female
| 1
| 6
|
Coma
|
Coma
| 0
| 9
|
under $11k
| 89
| 38,154
| 26,825.9531
| 20,579
| 44
|
white
| 20.199219
| 31
| 0.332947
| 0.260986
| 5
| 0
| 0
|
no
| 0
| 0
|
dnr after sadm
| 2
| 107
| 18
| 146
| 7
| 38.29688
| 292
| 3.399902
| 0.5
| 1.299805
| 147
| 7.459961
| 376
| 23
| 1,660
| null | null |
<2 mo. follow-up
| 2.086914
| 6
| 1
|
68.13696
|
female
| 0
| 4
|
Colon Cancer
|
Cancer
| 3
| 12
|
>$50k
| 0
| 7,693
| 4,762.9375
| 3,260
| 7
|
white
| 16.296875
| 12
| 0.820923
| 0.613892
| 1
| 1
| 0
|
metastatic
| null | null |
no dnr
| 4
| 108
| 16.5
| 76
| 24
| 36.5
| 164
| 4.399414
| 0.699951
| 1
| 137
| 7.30957
| 126
| 22
| 2,050
| null | null |
no(M2 and SIP pres)
| 1.982178
| 163
| 1
|
81.94897
|
female
| 0
| 14
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 10
|
under $11k
| 0
| 51,340
| 32,087.4375
| 32,062
| 21
|
white
| 26.296875
| 30
| 0.610962
| 0.504883
| 14
| 0
| 0
|
no
| 0
| 0
|
no dnr
| 14
| 62
| 5.699219
| 110
| 46
| 36.09375
| 165.6875
| null | null | 4.899414
| 128
| 7.399414
| 148
| 76
| 1,495
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 991
| 0
|
79.034
|
male
| 0
| 10
|
COPD
|
COPD/CHF/Cirrhosis
| 1
| 5
|
$11-$25k
| 0
| 14,735
| 9,159.4531
| 9,445
| 10.5
|
white
| 18.5
| 22
| 0.810913
| 0.69397
| 1
| 0
| 0
|
no
| 0.88
| 0.8
|
no dnr
| 10
| 117
| 2.899902
| 116
| 25
| 36.19531
| 190
| 3.099609
| 0.199982
| 0.199982
| 132
| 7.509766
| 213
| 18
| 3,375
| 1
| 2
|
no(M2 and SIP pres)
| 2
| 991
| 0
|
69.60699
|
female
| 0
| 3
|
Lung Cancer
|
Cancer
| 1
| 13
|
under $11k
| 0
| 5,958
| 2,977.6484
| 1,305
| 3
|
white
| 12.798828
| 11
| 0.774902
| 0.530884
| 1
| 0
| 0
|
metastatic
| 0.9
| 0.7
|
no dnr
| 3
| 128
| 32.5
| 134
| 8
| 35.79688
| 266.625
| 1.899902
| 0.799927
| 0.699951
| 141
| 7.459961
| 159
| 25
| 800
| 2
| null |
SIP>=30
| 1.838867
| 324
| 1
|
72.00494
|
female
| 0
| 6
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 6
| null | 9
| 68,144
| 47,068.375
| 41,204
| 32
|
white
| 35
| 59
| 0.379944
| 0.260986
| 24
| 0
| 0
|
no
| 0.2
| 0.5
|
dnr after sadm
| 3
| 73
| 11.298828
| 50
| 14
| 36.79688
| null | 3.099609
| 0.599976
| 0.5
| 136
| null | 92
| 11
| 450
| null | 3
|
<2 mo. follow-up
| 3
| 7
| 1
|
54.65799
|
male
| 0
| 6
|
Colon Cancer
|
Cancer
| 1
| null | null | 0
| 8,430
| 4,578.5547
| 2,552
| 11
|
white
| 13.398438
| 10
| 0.873901
| 0.716919
| 1
| 0
| 0
|
metastatic
| 0.8
| 0.6
|
no dnr
| 6
| 103
| 10.199219
| 140
| 24
| 36.5
| 225.90625
| null | null | 0.799927
| 136
| 7.459961
| 108
| 11
| 0
| null | null | null | 1.643311
| 330
| 1
|
36.38098
|
male
| 0
| 18
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 3
| 8
|
under $11k
| 0
| 41,443
| 27,296.5
| 26,221
| 22
|
white
| 22.597656
| 36
| 0.881958
| 0.839966
| 3
| 0
| 0
|
no
| 0.65
| 0.6
|
no dnr
| 18
| 70
| 4
| 80
| 28
| 36.09375
| null | null | 3.699707
| 1.199951
| 139
| null | 88
| 13
| 3,670
| 5
| 4
|
SIP>=30
| 4
| 989
| 0
|
72.56097
|
female
| 1
| 32
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 3
| 12
|
$11-$25k
| 0
| 263,761
| 154,728.25
| 154,703
| 35.25
|
white
| 29.796875
| 66
| 0.560913
| 0.448975
| 40
| 1
| 0
|
no
| 0.5
| 0.4
|
dnr after sadm
| 28
| 111
| 23.296875
| 110
| 10
| 35.89844
| 306.625
| 2.099609
| 1.399902
| 1.199951
| 135
| null | 253
| 8
| null | null | 0
|
<2 mo. follow-up
| 0
| 32
| 1
|
69.224
|
female
| 0
| 74
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 11
| null | 0
| 112,202
| 73,917.9375
| 89,256
| 14
|
white
| 27
| 42
| 0.702881
| 0.612915
| 4
| 0
| 0
|
no
| 0.75
| 0.7
|
no dnr
| 74
| 69
| 20.796875
| 116
| 45
| 36.89844
| 210
| 6
| null | 1.699951
| 134
| 7.5
| 101
| 59
| 2,885
| 0
| null |
no(M2 and SIP pres)
| 0.494751
| 988
| 0
|
69.41296
|
male
| 1
| 3
|
Coma
|
Coma
| 2
| 14
| null | 100
| 22,805
| 13,870.9531
| 11,851
| 30
|
white
| 76.6875
| 78
| 0
| 0
| 2
| 1
| 0
|
no
| 0
| 0
|
dnr after sadm
| 3
| 124
| 10.5
| 50
| 52
| 38.69531
| 121.42188
| null | 1.699951
| 0.899902
| 132
| 7.379883
| 223
| 10
| 3,115
| null | null |
<2 mo. follow-up
| 1.676025
| 3
| 1
|
92.07898
|
male
| 1
| 17
|
Coma
|
Coma
| 1
| 4
| null | 100
| 21,422
| 15,316.3672
| 13,817
| 15.333328
|
black
| 26.796875
| 49
| 0.014
| 0.006
| 1
| 0
| 0
|
no
| 0.1
| 0.05
|
dnr after sadm
| 2
| 139
| 13.5
| 52
| 20
| 36
| null | null | 0.399963
| 1.699951
| 141
| null | 156
| 26
| 4,530
| null | 3
|
<2 mo. follow-up
| 3
| 17
| 1
|
79.60596
|
female
| 1
| 15
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 4
| null |
under $11k
| 9
| 124,058
| 84,398.0625
| 67,341
| 34
|
white
| 22.898438
| 43
| 0.662964
| 0.565918
| 17
| 1
| 0
|
no
| 0.25
| 0.2
|
no dnr
| 15
| 109
| 5.199219
| 106
| 28
| 38.09375
| 240
| 3.099609
| 0.799927
| 0.799927
| 136
| 7.5
| 105
| 7
| 2,175
| null | 1
|
<2 mo. follow-up
| 1
| 15
| 1
|
60.08197
|
female
| 1
| 6
|
Coma
|
Coma
| 2
| null | null | 44
| 20,261
| 12,103.0781
| 11,114
| 35
|
white
| 31.097656
| 46
| 0.335999
| 0.263977
| 1
| 0
| 0
|
no
| 0.25
| 0.1
|
dnr after sadm
| 3
| 109
| 11.398438
| 130
| 42
| 38.19531
| 328.5625
| 2.399902
| 0.5
| 1.199951
| 146
| 7.40918
| 101
| 11
| 5,445
| null | null |
<2 mo. follow-up
| 2.287598
| 6
| 1
|
43.60599
|
male
| 0
| 15
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 13
|
>$50k
| 0
| 47,040
| null | null | 29
|
black
| 24.796875
| 39
| 0.859985
| 0.81189
| 1
| 0
| 0
|
no
| 0.5
| 0.5
|
no dnr
| 15
| 130
| 12.699219
| 105
| 22
| 36
| null | null | null | 1.199951
| 138
| null | 102
| 10
| null | null | 0
|
no(M2 and SIP pres)
| 0
| 985
| 0
|
52.90598
|
female
| 0
| 185
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 12
| null | 0
| 387,733
| 289,438.25
| 295,038
| 38.25
|
white
| 18.097656
| 36
| 0.876953
| 0.833984
| 6
| 1
| 0
|
no
| 0.5
| 0.25
|
no dnr
| 185
| 66
| 14.898438
| 120
| 30
| 38
| 260
| null | null | 1.299805
| 135
| 7.459961
| 362
| 17
| 2,130
| null | 5
| null | 5
| 441
| 1
|
56.36099
|
male
| 0
| 4
|
Lung Cancer
|
Cancer
| 0
| 14
|
$25-$50k
| 0
| 3,364
| 2,276.2129
| 1,885
| 4
|
white
| 5.899414
| 5
| 0.878906
| 0.726929
| 1
| 0
| 0
|
metastatic
| 0.75
| 0.6
|
no dnr
| 4
| 75
| 13
| 72
| 6
| 36.19531
| 180
| 2.299805
| null | 1.199951
| 141
| 7.449219
| 168
| 21
| 1,925
| null | null |
no(M2 and SIP pres)
| 1.554688
| 292
| 1
|
46.17398
|
female
| 1
| 39
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| null | null | 9
| 191,962
| 110,909.062
| 111,697
| 35
|
other
| 30.199219
| 38
| 0.738892
| 0.656982
| 2
| 0
| 0
|
no
| 0.3
| 0.25
|
no dnr
| 39
| 51
| 12.798828
| 114
| 8
| 36.79688
| 286.625
| null | null | 1.299805
| 133
| 7.429688
| 138
| 11
| 3,760
| null | 0
|
<2 mo. follow-up
| 0
| 39
| 1
|
75.55597
|
male
| 0
| 10
|
Colon Cancer
|
Cancer
| 2
| 11
|
$11-$25k
| 0
| 24,408
| 13,726.4297
| 14,629
| 23
|
other
| 38.5
| 34
| 0.272949
| 0.039993
| 1
| 1
| 0
|
metastatic
| null | null |
no dnr
| 10
| 122
| 17.398438
| 56
| 26
| 36.09375
| 177.125
| 2
| 0.699951
| 0.699951
| 141
| 7.419922
| 205
| 14
| 2,180
| 1
| 0
|
no(M2 and SIP pres)
| 0
| 339
| 1
|
74.06696
|
female
| 0
| 63
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 18
|
$25-$50k
| 44
| 351,646
| 235,729.75
| 203,126
| 32
|
white
| 29.597656
| 48
| 0.330994
| 0.215973
| 39
| 0
| 0
|
no
| 0
| 0
|
dnr after sadm
| 1
| 117
| 11.099609
| 104
| 22
| 38.09375
| null | null | 0.899902
| 0.799927
| 136
| null | 126
| 6
| 1,200
| null | null |
adl>=4 (>=5 if sur)
| 2.467773
| 984
| 0
|
77.97095
|
male
| 0
| 4
|
CHF
|
COPD/CHF/Cirrhosis
| 2
| 7
|
under $11k
| 0
| 12,064
| 6,601.418
| 6,840
| 21
|
white
| 27.199219
| 47
| 0.700928
| 0.53894
| 1
| 0
| 0
|
no
| 0.95
| 0.9
|
no dnr
| 4
| 110
| 13.099609
| 114
| 10
| 36.19531
| 280
| null | null | 1.399902
| 147
| 7.419922
| 149
| 32
| 1,190
| 1
| 0
| null | 0
| 757
| 1
|
64.79395
|
male
| 1
| 5
|
MOSF w/Malig
|
ARF/MOSF
| 2
| 12
|
under $11k
| 41
| 48,334
| null | null | 52
|
white
| 53.195313
| 95
| 0
| 0
| 15
| 0
| 0
|
metastatic
| 0.15
| 0.05
|
dnr after sadm
| 3
| 55
| 10.199219
| 120
| 34
| 35.89844
| 154.28125
| null | null | 3.799805
| 138
| 7.229492
| 83
| 58
| 65
| null | 0
|
<2 mo. follow-up
| 0
| 5
| 1
|
69.62396
|
male
| 0
| 5
|
Colon Cancer
|
Cancer
| 1
| 14
|
>$50k
| 0
| 8,843
| 4,625.3203
| 2,360
| 16
|
white
| 25
| 24
| 0.664917
| 0.363953
| 1
| 0
| 0
|
metastatic
| null | null |
no dnr
| 5
| 121
| 10.099609
| 124
| 16
| 38.89844
| 184
| null | 3.799805
| 1.799805
| 149
| 7.479492
| 151
| 55
| 5,600
| 1
| 1
|
no(M2 and SIP pres)
| 1
| 78
| 1
|
66.41498
|
female
| 1
| 12
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 3
| 11
|
under $11k
| 0
| 63,235
| 43,191.6875
| 33,924
| 49
|
white
| 36
| 67
| 0.514893
| 0.398987
| 3
| 0
| 0
|
no
| 0.3
| 0.25
|
dnr after sadm
| 10
| 69
| 9.298828
| 114
| 33
| 38
| 233.3125
| 2.699707
| 0.899902
| 0.899902
| 134
| 7.489258
| 135
| 17
| 2,980
| null | 6
|
<2 mo. follow-up
| 6
| 12
| 1
|
43.88797
|
male
| 1
| 3
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 14
|
under $11k
| 0
| 33,859
| 20,129.8125
| 19,062
| 40
|
white
| 78.390625
| 101
| 0
| 0
| 6
| 0
| 0
|
no
| null | null |
dnr after sadm
| 2
| 73
| 11.599609
| 66
| 43
| 36.89844
| 171.40625
| null | null | 0.599976
| 143
| 7.459961
| 144
| 19
| 5,270
| null | null |
<2 mo. follow-up
| 1.300293
| 3
| 1
|
64.60498
|
female
| 0
| 11
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 3
| 12
|
$11-$25k
| 26
| 20,922
| 14,122.8906
| 12,004
| 19.5
|
white
| 34.195313
| 67
| 0.324951
| 0.209991
| 6
| 0
| 0
|
yes
| 0.8
| 0.75
|
no dnr
| 11
| 77
| 11.898438
| 84
| 10
| 38.39844
| 205
| null | null | 0.599976
| 135
| 7.359375
| 131
| 7
| 4,025
| 1
| 1
|
no(M2 and SIP pres)
| 1
| 685
| 1
|
25.83699
|
male
| 0
| 13
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 16
| null | 0
| 37,859
| 26,204.4531
| 19,260
| 36
|
white
| 28.898438
| 36
| 0.860962
| 0.812988
| 1
| 0
| 0
|
no
| 0.7
| 0.7
|
no dnr
| 13
| 55
| 17.597656
| 100
| 9
| 35.69531
| 120
| null | 2.5
| 6.399414
| 132
| 7.439453
| 163
| 52
| 0
| null | 0
|
no(M2 and SIP pres)
| 0
| 979
| 0
|
53.27597
|
male
| 0
| 5
|
Colon Cancer
|
Cancer
| 1
| null | null | 0
| 4,133
| 2,510.0586
| 1,991
| 11
|
white
| 15.599609
| 11
| 0.853882
| 0.675903
| 1
| 0
| 0
|
metastatic
| 0.7
| 0.3
|
no dnr
| 5
| 117
| 11.199219
| 64
| 28
| 36.89844
| null | 3.899902
| 0.899902
| 0.699951
| 138
| null | 269
| 14
| 2,575
| null | null | null | 1.698486
| 112
| 1
|
76.84094
|
female
| 1
| 29
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 12
|
under $11k
| 0
| 197,568
| 125,466.125
| 105,323
| 50.25
|
white
| 31.597656
| 60
| 0.522949
| 0.407959
| 8
| 0
| 0
|
no
| 0.5
| 0.125
|
dnr after sadm
| 29
| 0
| 15.699219
| 0
| 8
| 35.39844
| 172.5
| 1
| 1.099854
| 2.699707
| 129
| 7.299805
| 393
| 40
| 0
| null | 0
|
<2 mo. follow-up
| 0
| 29
| 1
|
73.45099
|
male
| 0
| 17
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| null | null | 61
| 49,163
| 31,625.6719
| 30,657
| 13.333328
|
white
| 21.296875
| 28
| 0.56189
| 0.448975
| 4
| 0
| 0
|
no
| 0.05
| 0
|
dnr after sadm
| 4
| 137
| 12.898438
| 66
| 12
| 38.19531
| 222.84375
| null | null | 0.899902
| 150
| 7.5
| 113
| 20
| 4,445
| null | 6
|
<2 mo. follow-up
| 6
| 28
| 1
|
54.74298
|
male
| 0
| 11
|
Lung Cancer
|
Cancer
| 1
| 12
|
$25-$50k
| 0
| 12,573
| 7,762.1016
| 7,355
| 9
|
white
| 24.597656
| 31
| 0.560913
| 0.238983
| 1
| 0
| 0
|
metastatic
| null | null |
no dnr
| 11
| 36
| 1.199951
| 30
| 33
| 37.59375
| 93.875
| null | null | 1.899902
| 143
| 7.40918
| 98
| 32
| 110
| null | 0
|
adl>=4 (>=5 if sur)
| 0
| 92
| 1
|
68.35297
|
male
| 0
| 9
|
Lung Cancer
|
Cancer
| 1
| null | null | 0
| 10,104
| 6,418.5742
| 6,909
| 11
|
white
| 12.798828
| 21
| 0.775879
| 0.532959
| 1
| 0
| 0
|
metastatic
| null | null |
no dnr
| 9
| 76
| 9.898438
| 56
| 8
| 36
| 332
| null | null | 1.299805
| 131
| 7.379883
| 116
| 17
| 1,165
| null | 0
|
<2 mo. follow-up
| 0
| 36
| 1
|
66.00995
|
male
| 0
| 11
|
CHF
|
COPD/CHF/Cirrhosis
| 4
| 14
|
$11-$25k
| 0
| 16,025
| 12,553.1641
| 7,611
| 11
|
white
| 12.298828
| 25
| 0.901978
| 0.834961
| 1
| 1
| 0
|
yes
| 0.75
| 0.5
|
no dnr
| 11
| 153
| 15.898438
| 140
| 14
| 36.89844
| 280
| 4
| 0.399963
| 0.599976
| 143
| 7.479492
| 186
| 23
| 2,510
| 0
| null |
no(M2 and SIP pres)
| 0.494751
| 430
| 1
|
62.15698
|
female
| 0
| 18
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 4
| 8
|
under $11k
| 0
| 43,691
| 27,075.0625
| 25,739
| 22
|
black
| 38.195313
| 53
| 0.526978
| 0.41095
| 1
| 0
| 0
|
no
| 0.7
| 0.6
|
no dnr
| 18
| 109
| 6.399414
| 170
| 10
| 38.69531
| 210
| 1.5
| 1.899902
| 0.5
| 137
| 7.40918
| 94
| 12
| 1,963
| null | null |
no(M2 and SIP pres)
| 3.624512
| 977
| 0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.